In an effort to combat the growing threat of synthetic opioids, the Shapiro Administration has temporarily classified Nitazenes as a Schedule I controlled substance in Pennsylvania, effective Saturday, July 19.

Nitazenes, a class of powerful synthetic opioids often stronger than fentanyl, have been linked to 45 overdose deaths in Pennsylvania since 2023. State officials say the move gives law enforcement more authority to address the drug’s rising presence in the illicit supply.

“Scheduling Nitazenes, which have no acceptable medical use, as Class I substances provides law enforcement with the authority to crack down on its possession and distribution,” said Secretary of Health Dr. Debra Bogen. “Our focus remains on developing strategies that connect people with treatment and other resources.”

The temporary scheduling is valid for two years under state law, while the Department of Health works to make the classification permanent. This action aligns with the U.S. Drug Enforcement Administration’s determination that Nitazenes pose a significant hazard to public safety due to their potency, lack of medical use, and risk of fatal overdose.

As synthetic opioids remain a leading driver of overdose deaths, health officials stress the importance of naloxone, an opioid-reversal medication, and encourage Pennsylvanians to learn how to access and administer it.

More information is available on the Department of Health’s website.